Kelly graduated in 2012 with a bachelor’s degree in biomedical engineering from the University of Texas at Austin. At UT, in Dr. George Georgiou’s lab, Kelly worked on novel techniques for characterizing serum antibody repertoires following immunization. During her undergraduate education, she studied abroad at the University of Cambridge and interned with Merck & Co., Inc. in their viral vaccine division. Kelly Moynihan is now pursuing a PhD in biological engineering at MIT in Darrell Irvine’s Immunobioengineering laboratory. Kelly is interested in engineering the immune system to generate effective anti-tumor responses through novel vaccination strategies and combination immunotherapy. She has developed and characterized an immunotherapy regiment that is capable of inducing regression in large, established murine tumors of many types by engaging both innate and adaptive immune effectors. This therapy is not cell-based, is composed of injectables, and can induce complete regression of tumor burdens that were previously not treatable using therapies that rely on endogenous immune responses. Outside the lab, Kelly enjoys teaching and STEM outreach. For the last three years Kelly has been involved with an educational start-up called The Innovation Institute, which aims to foster creativity in K-12 students through challenging, inquiry based classes focusing on science and engineering. Through this organization, she co-developed and implemented a 3D printing summer camp for middle school students, which debuted in summer 2014. She developed and twice implemented a high school class entitled “At the Frontiers,” which focused on one cutting edge technology or research area for each class, with discussions, demonstrations, and hands-on experiments to enhance learning.